ATAI Life Sciences N.V. (ATAI, Financial) saw its stock price fall by 5.03%, trading at $1.61 per share with a volume of 689,255 shares. The stock's turnover rate was 0.41%, and it experienced a price fluctuation of 4.14%. Recent financial reports show ATAI's revenue at $40,000, with a net loss of $26.29 million, resulting in an earnings per share of -$0.16 and a gross loss of $43,000. The price-to-earnings ratio stands at -2.04, with no current institutional ratings.
The biotech sector, where ATAI operates, recorded an overall decline of 0.82%. Notable gains in the sector were seen in Pasithea Therapeutics Corp, Jupiter Neurosciences Inc, and Tc Biopharm (Holdings) Plc. Meanwhile, Quoin Pharmaceuticals Ltd, Nls Pharmaceutics Ltd., and Purple Biotech Ltd were particularly active, showing high turnover rates.
ATAI Life Sciences is a clinical-stage biopharmaceutical company focused on transforming mental health treatment, with operations in the U.S. and Germany.
